WO2018120843A9 - 一种三功能分子及其应用 - Google Patents

一种三功能分子及其应用 Download PDF

Info

Publication number
WO2018120843A9
WO2018120843A9 PCT/CN2017/096594 CN2017096594W WO2018120843A9 WO 2018120843 A9 WO2018120843 A9 WO 2018120843A9 CN 2017096594 W CN2017096594 W CN 2017096594W WO 2018120843 A9 WO2018120843 A9 WO 2018120843A9
Authority
WO
WIPO (PCT)
Prior art keywords
trifunctional molecule
functional domain
application
cell
cells
Prior art date
Application number
PCT/CN2017/096594
Other languages
English (en)
French (fr)
Other versions
WO2018120843A1 (zh
Inventor
陈帅
朱化星
廖远平
Original Assignee
上海近岸生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201611258691.0A external-priority patent/CN108264559B/zh
Priority claimed from CN201611256659.9A external-priority patent/CN108264558B/zh
Priority claimed from CN201611260817.8A external-priority patent/CN108264561B/zh
Priority claimed from CN201611258643.1A external-priority patent/CN106589129B/zh
Application filed by 上海近岸生物科技有限公司 filed Critical 上海近岸生物科技有限公司
Priority to US16/474,555 priority Critical patent/US11535666B2/en
Priority to EP17888652.9A priority patent/EP3564265A4/en
Publication of WO2018120843A1 publication Critical patent/WO2018120843A1/zh
Publication of WO2018120843A9 publication Critical patent/WO2018120843A9/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

提供一种三功能分子及其应用。所述三功能分子的结构中包括第一功能域、第二功能域和第三功能域，能够同时结合CD19、CD3和T细胞正（负）共刺激因子，从而产生T细胞活化所需的第一信号和第二信号，在赋予T细胞对CD19阳性细胞靶向性的同时进一步提高了活化T细胞的功效。所述三功能分子为重组蛋白肽链，可采用真核细胞表达系统生产。
PCT/CN2017/096594 2016-12-30 2017-08-09 一种三功能分子及其应用 WO2018120843A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/474,555 US11535666B2 (en) 2016-12-30 2017-08-09 Trifunctional molecule and application thereof
EP17888652.9A EP3564265A4 (en) 2016-12-30 2017-08-09 TRIFUNCTIONAL MOLECULE AND ITS APPLICATION

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN201611258643.1 2016-12-30
CN201611260817.8 2016-12-30
CN201611256659.9 2016-12-30
CN201611258691.0 2016-12-30
CN201611258691.0A CN108264559B (zh) 2016-12-30 2016-12-30 一种结合cd19、cd3和t细胞正共刺激分子的三功能分子及其应用
CN201611256659.9A CN108264558B (zh) 2016-12-30 2016-12-30 融合抗cd19、抗cd3抗体结构域和t细胞正共刺激分子配体的三特异性分子及应用
CN201611260817.8A CN108264561B (zh) 2016-12-30 2016-12-30 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用
CN201611258643.1A CN106589129B (zh) 2016-12-30 2016-12-30 一种结合cd19、cd3和cd28的三功能分子及其应用

Publications (2)

Publication Number Publication Date
WO2018120843A1 WO2018120843A1 (zh) 2018-07-05
WO2018120843A9 true WO2018120843A9 (zh) 2019-02-14

Family

ID=62707876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/096594 WO2018120843A1 (zh) 2016-12-30 2017-08-09 一种三功能分子及其应用

Country Status (3)

Country Link
US (1) US11535666B2 (zh)
EP (1) EP3564265A4 (zh)
WO (1) WO2018120843A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
WO2021178973A1 (en) * 2020-03-06 2021-09-10 Albert Einstein College Of Medicine Compositions and methods for chimeric antigen receptor (car)-modified cell modulation
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2023147293A2 (en) * 2022-01-25 2023-08-03 The Trustees Of The University Of Pennsylvania Compositions and methods comprising anti-cd38 chimeric antigen receptors (cars)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176574T3 (es) * 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
WO2004106381A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
CN100376599C (zh) * 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
US9701759B2 (en) * 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
KR20160029128A (ko) * 2013-07-12 2016-03-14 자임워크스 인코포레이티드 이중특이적 cd3 및 cd19 항원 결합 구조체
CN107106609A (zh) 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 刺激和扩展t细胞的组合物和方法
EP3245227A4 (en) * 2015-01-14 2018-07-25 Compass Therapeutics LLC Multispecific immunomodulatory antigen-binding constructs
CN104829727B (zh) * 2015-01-21 2019-03-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd19×cd3的构建及应用
GB201503500D0 (en) * 2015-03-02 2015-04-15 Ucl Business Plc Cell
CN104788573B (zh) 2015-05-08 2018-10-16 中国医学科学院血液病医院（血液学研究所） 嵌合抗原受体hCD19scFv-CD8α-CD28-CD3ζ及其用途
CN106188305A (zh) 2015-06-01 2016-12-07 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
CN106117366A (zh) 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种cd19特异性嵌合抗原受体及其编码基因、应用
CN106589129B (zh) * 2016-12-30 2021-03-05 上海近岸生物科技有限公司 一种结合cd19、cd3和cd28的三功能分子及其应用

Also Published As

Publication number Publication date
WO2018120843A1 (zh) 2018-07-05
EP3564265A1 (en) 2019-11-06
US20200207851A1 (en) 2020-07-02
US11535666B2 (en) 2022-12-27
EP3564265A4 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
WO2018120843A9 (zh) 一种三功能分子及其应用
EA202092945A1 (ru) Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии
PH12019502294A1 (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
WO2019126634A3 (en) Targeted integration of nucleic acids
EP4317180A3 (en) Trifunctional t cell-antigen coupler and methods and uses thereof
EP4371570A3 (en) Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
WO2019008123A3 (en) CELLS, VERTEBRATES, POPULATIONS AND METHODS
CL2015002669A1 (es) Polipeptidos que contienen región fc aglicosilada
AU2018338418A1 (en) Anti-HLA-A2 antibodies and methods of using the same
AU2018258049A1 (en) Constructs specifically recognizing glypican 3 and uses thereof
EA201890390A1 (ru) БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3
PH12015502039A1 (en) Anti-lag-3 binding proteins
MY186708A (en) Constructs targeting afp peptide/mhc complexes and uses thereof
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201591376A1 (ru) Конструкции антител к cdh19 и cd3
IN2014MN01879A (zh)
WO2015049517A3 (en) Animal models and therapeutic molecules
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
AU2016335217A8 (en) Antigen receptors and uses thereof
EP2542581A4 (en) SPECIFIC APOLIPOPROTEIN ANTIBODY AND METHODS OF USING SAME
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
BR112015021993A2 (pt) composições de cultura celular com antioxidantes e métodos para produção de polipeptídeo

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17888652

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017888652

Country of ref document: EP

Effective date: 20190730